-
ABOS Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Acumen Pharmaceuticals (ABOS)
Company Profile
Quarter (USD) | Sep 24 | Mar 24 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 33.42 mm | 33.42 mm | 33.42 mm | 33.42 mm | 33.42 mm | |
Cash burn (monthly) | 4.58 mm | 3.71 mm | 10.76 mm | 6.63 mm | 3.54 mm | |
Cash used (since last report) | 12.82 mm | 10.39 mm | 30.09 mm | 18.55 mm | 9.89 mm | |
Cash remaining | 20.60 mm | 23.03 mm | 3.33 mm | 14.87 mm | 23.53 mm | |
Runway (months of cash) | 4.5 | 6.2 | 0.3 | 2.2 | 6.7 |
13F holders | Current |
---|---|
Total holders | 84 |
Opened positions | 36 |
Closed positions | 16 |
Increased positions | 18 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 102.76 bn |
Total shares | 47.27 mm |
Total puts | 65.90 k |
Total calls | 238.60 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 14.93 mm | $36.14 bn |
Sands Capital Ventures | 3.42 mm | $8.27 bn |
BEN Franklin Resources | 3.37 mm | $8.15 bn |
Paul B Manning | 2.55 mm | $0.00 |
Rock Springs Capital Management | 2.30 mm | $5.57 bn |
BLK BlackRock | 2.16 mm | $5.22 bn |
FMR | 2.02 mm | $4.89 bn |
Millennium Management | 1.95 mm | $4.73 bn |
Vanguard | 1.90 mm | $4.59 bn |
Knollwood Investment Advisory | 1.63 mm | $3.94 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Nov 24 | Amy Schacterle | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.95 | 340,000 | 1.00 mm | 340,000 |
10 Jun 24 | Drapkin Kimberlee C | Stock Option Common Stock | Grant | Acquire A | No | No | 2.62 | 25,000 | 65.50 k | 25,000 |
10 Jun 24 | Sean Stalfort | Stock Option Common Stock | Grant | Acquire A | No | No | 2.62 | 25,000 | 65.50 k | 25,000 |
10 Jun 24 | Derrell Porter | Stock Option Common Stock | Grant | Acquire A | No | No | 2.62 | 25,000 | 65.50 k | 25,000 |